行情

ONCT

ONCT

Oncternal Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

6.03
-0.05
-0.82%
已收盘, 16:08 11/14 EST
开盘
6.10
昨收
6.08
最高
6.29
最低
5.94
成交量
5.83万
成交额
--
52周最高
17.92
52周最低
3.430
市值
9,278.51万
市盈率(TTM)
-0.7462
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ONCT 新闻

  • 沪指周跌2.46% 隔夜美联储官员密集讲话
  • 新浪财经.1小时前
  • 阿里巴巴15日正式启动香港上市
  • 新华网.3小时前
  • 沃尔玛Q3在线销售增长41% 与亚马逊战争全面开启?
  • 新浪财经-自媒体综合.3小时前
  • 英国未提名欧盟委员 欧盟料采取法律行动
  • 汇通网.4小时前

更多

所属板块

生物技术和医学研究
-0.05%
制药与医学研究
-0.27%

热门股票

名称
价格
涨跌幅

ONCT 简况

Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.
展开

Webull提供Oncternal Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。